gptkbp:instance_of
|
gptkb:pharmaceuticals
|
gptkbp:administered_by
|
intramuscular injection
|
gptkbp:approves
|
gptkb:1996
|
gptkbp:chemical_formula
|
C634 H1009 N169 O198 S4
|
gptkbp:clinical_trial
|
Phase III
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to interferon beta
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
gptkbp:drug_interactions
|
anticoagulants
antidepressants
other immunosuppressants
|
gptkbp:effective_date
|
1996-04-01
|
gptkbp:financial_support
|
Avonex Support Program
|
gptkbp:formulation
|
lyophilized powder
|
gptkbp:frequency
|
once a week
|
https://www.w3.org/2000/01/rdf-schema#label
|
Avonex
|
gptkbp:indication
|
gptkb:relapsing_forms_of_multiple_sclerosis
|
gptkbp:ingredients
|
interferon beta-1a
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
|
gptkbp:manufacturer
|
gptkb:Biogen
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
gptkbp:mechanism_of_action
|
immunomodulatory
|
gptkbp:patient_education
|
storage instructions
side effects management
injection technique
when to seek medical attention
|
gptkbp:patient_population
|
adults
children over 12 years
|
gptkbp:pharmacokinetics
|
excreted in urine
metabolized in the liver
subcutaneous absorption
half-life of 8 hours
|
gptkbp:previous_name
|
interferon beta-1a
|
gptkbp:price
|
approximately $60,000 per year
varies by insurance
|
gptkbp:provides_guidance_on
|
MS treatment guidelines
neurology practice guidelines
|
gptkbp:recommissioned
|
with sterile water for injection
|
gptkbp:route_of_administration
|
intramuscular
|
gptkbp:side_effect
|
gptkb:anemia
gptkb:depression
fatigue
headache
muscle pain
injection site reactions
thrombocytopenia
flu-like symptoms
elevated liver enzymes
|
gptkbp:storage
|
refrigerated
|
gptkbp:trade
|
gptkb:Avonex
|
gptkbp:used_for
|
gptkb:multiple_sclerosis
|
gptkbp:weight
|
150 k Da
|
gptkbp:bfsParent
|
gptkb:Biogen_MA_Inc.
gptkb:Biogen_Idec
gptkb:Biogen_Inc.
gptkb:Rebif
gptkb:BIIB
|
gptkbp:bfsLayer
|
5
|